1h Free Analyst Time
The mycoplasma testing market is forecasted to grow by USD 645.51 mn during 2022-2027, accelerating at a CAGR of 12.25% during the forecast period. The report on the mycoplasma testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing focus on R and D of biopharmaceuticals, growing geriatric population, and rise in adoption of real-time mycoplasma testing.
The mycoplasma testing market is segmented as below:
By End-user
- Pharmaceutical and biotechnology comp.
- Cell banks
- Academic research institutes
- CROs
- Others
By Product
- Consumables
- Systems
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the mycoplasma testing market covers the following areas:
- Mycoplasma testing market sizing
- Mycoplasma testing market forecast
- Mycoplasma testing market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global mycoplasma testing market: Agilent Technologies Inc., ATCC, Akron Biotechnology LLC, Becton Dickinson and Co., Bio Techne Corp., Bionique Testing Laboratories Inc., Charles River Laboratories International Inc., DiaSorin SpA, Dilarus GmbH, F. Hoffmann La Roche Ltd., GeneCopoeia Inc., InvivoGen Corp., Lonza Group Ltd., Merck KGaA, Norgen Biotek Corp., PromoCell GmbH, Sartorius AG, ScienCell Research Laboratories Inc., SGS SA, and Thermo Fisher Scientific Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is increasing initiatives for rapid diagnostics of infectious diseases.'
According to the report, one of the major drivers for this market is the growing geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Agilent Technologies Inc.
- ATCC
- Akron Biotechnology LLC
- Becton Dickinson and Co.
- Bio Techne Corp.
- Bionique Testing Laboratories Inc.
- Charles River Laboratories International Inc.
- DiaSorin SpA
- Dilarus GmbH
- F. Hoffmann La Roche Ltd.
- GeneCopoeia Inc.
- InvivoGen Corp.
- Lonza Group Ltd.
- Merck KGaA
- Norgen Biotek Corp.
- PromoCell GmbH
- Sartorius AG
- ScienCell Research Laboratories Inc.
- SGS SA
- Thermo Fisher Scientific Inc.